おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
OMEICOS Therapeutics
company
About
OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- €17M
- Industries
- Health Care,Medical,Therapeutics
- Founded date
- Jan 1, 2013
- Number Of Employee
- 11 - 50
- Operating Status
- Active
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
€17M
OMEICOS Therapeutics has raised a total of
€17M
in funding over 2 rounds. Their latest funding was raised on
Nov 2, 2018 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 2, 2018 | Series C | €17M | 1 |
|
— | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
